742102-31-4

Basic information

• Product Name: tert-butyl(Z)-((3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio)methylene)carbamate
• Synonyms: tert-butyl(Z)-((3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio)methylene)carbamate;EOS-60896;Carbamic acid, N-[[[(3,5-diamino-6-chloro-2-pyrazinyl)carbonyl]imino](methylthio)methyl]-, 1,1-dimethylethyl ester
• CAS NO: 742102-31-4
• Molecular Formula: C₁₂H₁₇ClN₆O₃S
• Molecular Weight: 362.83566
• Mol File: 742102-31-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl(Z)-((3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio)methylene)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl(Z)-((3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio)methylene)carbamate(742102-31-4)
• EPA Substance Registry System: tert-butyl(Z)-((3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio)methylene)carbamate(742102-31-4)

Safety Data

• Hazardous Substances Data: 742102-31-4(Hazardous Substances Data)

Upstream product

• 76942-92-2 methyl 3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate hydroiodic acid salt 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1458-01-1 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid methyl ester 
• 1080018-69-4 3,5-diamino-6-chloropyrazine-2-carboxylic acid lithium salt 
• 173998-77-1 tert-butyl [amino(methylthio)methylene]carbamate 
• 1122-58-3 dmap 

Downstream Products

• 1080018-66-1 tert-butyl (1,1'-(1,4-phenylene)bis(oxomethylene)bis(piperidine-4,1-diyl))bis(azanediyl)bis((3,5-diamino-6-chloropyrazine-2-carboxamido)methan-1-yl-1-ylidene)dicarbamate 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

ORGANIC COMPOUNDS

A compound of formula (I), or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M2, L1, L2, W1, W2, X1, X2, Y1/